Reviews
COVID-19 vaccine landscape
Authors:
S. L. Seneviratne ,
Royal Free Hospital and University College London, London, GB
About S. L.
Institute of Infection and Immunity
Department of Surgery, Faculty of Medicine, University of Colombo
Nawaloka Hospital Research and Education Foundation, Nawaloka Hospitals PLC, Colombo
U. Jayarajah,
University of Colombo, LK
About U.
Department of Surgery, Faculty of Medicine
V. Abeysuriya,
Nawaloka Hospitals PLC, Colombo, LK
About V.
Nawaloka Hospital Research and Education Foundation
A. Rahman,
University of Colombo, LK
About A.
Department of Surgery, Faculty of Medicine
K. Wanigasuriya
University of Sri Jayewardenepura, LK
About K.
Department of Medicine, Faculty of Medicine
Abstract
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is currently pandemic, and as of 15th November 2020, there have been 53.7 million confirmed cases worldwide and around 1.3 million deaths. The availability of an effective vaccine is the best long-term answer to the current COVID-19 pandemic. More than 210 candidate vaccines have come into development since the start of the pandemic. Eleven vaccines (ten of them specifically directed against SARS-CoV-2) have entered phase 3 clinical trials. Five of these vaccines have also been approved for early or limited use. This review outlines information on the current COVID-19 vaccine pipeline, discusses the pros and cons of different vaccine delivery systems and the steps involved in getting a safe and effective vaccine to the global population.
How to Cite:
Seneviratne, S.L., Jayarajah, U., Abeysuriya, V., Rahman, A. and Wanigasuriya, K., 2020. COVID-19 vaccine landscape. Journal of the Ceylon College of Physicians, 51(2), pp.120–131. DOI: http://doi.org/10.4038/jccp.v51i2.7906
Published on
14 Dec 2020.
Peer Reviewed
Downloads
